Alvotech Announces $150M Licensing And Commercialization Agreement With Lotus Pharmaceutical Plus Milestone Payments For Durvalumab, Emicizumab Biosimilars In U.S. And Eight Asian Markets
Share
Why It Matters
Alvotech made a deal to sell copies of two important medicines in the U.S. and Asia, earning $150 million upfront plus extra money if things go well. This shows a big company believes in Alvotech's products, which is a sign they're doing something right.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.